Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Immediate Release (IR) Formulation
Immediate Release Formulation · 1 trial · 1 indication
DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and included the below, if judged by the investigator/medical monitor to be possibly related to study treatment: Non-hematologic DLTs were any ≥ Grade 3 toxicity, except: Grade 3 asymptomatic electrolyte abnormalities (except hypophosphatemia \> 24 hours); Grade 3 nausea, vomiting and diarrhea \< 3 days; Grade 3 fatigue \< 14 days; ≥ Grade 3 hyperglycemia/toxicity due to dexamethasone; ≥ Grade 3 rash due to pomalidomide. Hematologic DLTs included: Grade 4 neutropenia if absolute neutrophil count \< 0.5 x 10\^9/L ≥ 7 days; febrile neutropenia; Grade 4 thrombocytopenia ≥ 7 days; Grade ≥ 3 with ≥ Grade 2 bleeding/requiring platelet transfusion.
The MTD was the dose with the highest posterior probability of having a DLT rate within the target toxicity interval (15% to 25%), while the posterior probability of excessive/unacceptable toxicity (\>25% to 100%) is \<40%. DLTs were graded using CTCAE version 4.03 and included the below, if judged by the investigator/medical monitor to be possibly related to study treatment: Non-hematologic DLTs were any ≥ Grade 3 toxicity, except: Grade 3 asymptomatic electrolyte abnormalities (except hypophosphatemia \> 24 hours); Grade 3 nausea, vomiting and diarrhea \< 3 days; Grade 3 fatigue \< 14 days; ≥ Grade 3 hyperglycemia/toxicity due to dexamethasone; ≥ Grade 3 rash due to pomalidomide. Hematologic DLTs included: Grade 4 neutropenia if absolute neutrophil count \< 0.5 x 10\^9/L ≥ 7 days; febrile neutropenia; Grade 4 thrombocytopenia ≥ 7 days; Grade ≥ 3 with ≥ Grade 2 bleeding/requiring platelet transfusion.
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. TEAEs were any AE that started on or after receiving the first dose of investigational product and up to and including 30 days after the last dose of investigational product or the end of study date, whichever is earlier. Treatment-related TEAEs were those considered related to study treatment by the investigator. Any clinically significant changes in electrocardiograms, vital signs, physical examination with a neurological assessment and clinical laboratory tests were recorded as TEAEs.
TEAEs were any AE that started on or after receiving the first dose of investigational product and up to and including 30 days after the last dose of investigational product or the end of study date, whichever is earlier. Treatment-related TEAEs were those considered related to study treatment by the investigator. Serious TEAEs were any AE meeting at least 1 of the following criteria: fatal; life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event.
| Arm | Type | Description |
|---|---|---|
| Part 1 Oprozomib Immediate-release (IR) + Dexamethasone | EXPERIMENTAL | Oprozomib IR plus dexamethasone |
| Part 1 Oprozomib Gastro-retentive (GR) + Dexamethasone | EXPERIMENTAL | Oprozomib GR plus dexamethasone |
| Part 2 Oprozomib IR + Pomalidomide + Dexamethasone | EXPERIMENTAL | Oprozomib IR plus pomalidomide and dexamethasone |
| Part 2 Oprozomib GR + Pomalidomide + Dexamethasone | EXPERIMENTAL | Oprozomib GR plus pomalidomide and dexamethasone |
| Open-label Roll-over | EXPERIMENTAL | Oprozomib GR monotherapy, or oprozomib GR plus dexamethasone |
| Name | Type | Description |
|---|---|---|
| Immediate Release (IR) Formulation | DRUG | Immediate Release (IR) Formulation |
| Gastro-Retentive (GR) Formulation | DRUG | Gastro-Retentive (GR) Formulation |
| Dexamethasone | DRUG | Dexamethasone |
| Pomalidomide | DRUG | Pomalidomide |
Inclusion criteria * Participant must have a pathologically documented, definitively diagnosed, multiple myeloma relapse, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include a proteasome inhibitor and lenalid...
Top 20 of 25 competitors
The Immediate Release Formulation is being studied in relapsed or refractory multiple myeloma, a blood cancer that has returned or stopped responding to prior treatment. It is an oncology asset developed by Amgen Inc. and is given to adult patients aged 18 years and older in this indication.
Amgen Inc. (ticker AMGN) is the developer of the Immediate Release Formulation. The company is evaluating it in relapsed or refractory multiple myeloma as part of its oncology pipeline.
The Immediate Release Formulation is in Phase 1 development. It has not been approved and remains investigational. One Phase 1b trial has been completed, and no trials are currently active.
The Immediate Release Formulation has been evaluated in one Phase 1b trial, NCT02939183, titled a Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma. That trial enrolled 61 participants across the United States, Australia, Canada, and Spain and is now completed.
Yes. The Immediate Release Formulation is also known as the Immediate Release (IR) Formulation. Both names refer to the same Amgen Inc. oncology asset being studied in relapsed or refractory multiple myeloma.